Lumos Pharma, Inc. (LUMO)

Tentang perusahaan

Lumos Pharma, Inc., formerly NewLink Genetics Corporation, is a clinical stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for rare diseases. Its lead product candidate is LUM-201, an oral growth hormone stimulating therapeutic, is in late stage clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). LUM-201 is an orally administered small molecule that promotes the secretion (secretagogue) of Growth Hormone (GH) from the pituitary gland. LUM-201 acts as an agonist of the GH Secretagogue Receptor to stimulate GH release. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.